Catalent Appoints Three Industry Leaders to Board
Catalent has appointed Susan Mahony (formerly of Eli Lilly), Marie-France Tschudin (ex-Novartis executive), and Tim Walbert (CEO of Horizon Therapeutics) to its Board of Directors as the company looks to strengthen its position as an independent CDMO under Novo Holdings' ownership. With a seven-member board, Catalent aims to enhance its manufacturing and supply capabilities under new ownership and will continue to support its pharmaceutical and biotech customers worldwide.
Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership.
Alessandro Maselli, President and CEO, and Board member of Catalent, said “I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech customers. Susan, Marie-France and Tim are each accomplished leaders who bring the right balance of industry experience and fresh perspective to achieve the vision for Catalent’s next chapter.”
“We are thrilled to welcome these biopharma leaders to our Board, whose expertise in navigating the complexities of the healthcare landscape will be invaluable,” said John Greisch, Chair of the Board. “We look forward to benefitting from their insights in support of Catalent’s mission to develop, manufacture and supply products that help people live better and healthier lives.”
The Catalent Board also includes Jonathan Levy, Senior Partner at Novo Holdings, and Charles Patten, Partner at Novo Holdings, both of whom joined the Board upon Catalent becoming a private company following the completion of the acquisition by Novo Holdings in December 2024.
“On behalf of Novo Holdings, I am pleased to welcome our new Board members, said Jonathan Levy, Senior Partner, Novo Holdings. “Their diverse expertise and strategic insight will strengthen Catalent’s operations as an independent CDMO. We look forward to their contributions as we shape the company’s next chapter of growth and continued focus on improving the lives of patients worldwide.”
The appointment of these new Board Directors is effective immediately and completes the Company’s updates to its Board, which is now comprised of 7 directors.
For more, please find the original story source here.